Inactive Instrument

Highlights Opko Health Inc. Nyse

Equities

US68375N1037

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
OPKO Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (OPK) OPKO HEALTH Posts Q3 Revenue $178.6M, vs. Street Est of $174.8M	Nov. 06	MT
OPKO Health, Inc. Presents Late-Breaking Clinical Data on RAYALDEE Extended-Release Calcifediol	Nov. 02	CI
OPKO Health Subsidiary Lands BARDA Contract	23-09-28	MT
OPKO Health Shares Jump on Better-Than-Expected Q2 Results	23-08-04	MT
Earnings Flash (OPK) OPKO HEALTH Reports Q2 Revenue $265.4M, vs. Street Est of $202M	23-08-03	MT
OPKO Health, Inc. Provides Revenue Guidance for the Third Quarter of 2023	23-08-03	CI
OPKO Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
US FDA approves Pfizer's drug for growth hormone deficiency	23-06-28	RE
Weight-loss drugs: the next gold rush	23-05-12	RE
Earnings Flash (OPK) OPKO HEALTH Reports Q1 Revenue $237.6M, vs. Street Est of $193.4M	23-05-03	MT
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
OPKO Health Subsidiary Working With Merck to Develop Epstein-Barr Virus Vaccine Candidate	23-03-08	MT
Merck & Co, OPKO Health's ModeX to Collaborate on Epstein-Barr Virus Vaccine Candidate	23-03-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Opko Health Inc. Nyse

Equities

US68375N1037

Highlights

Filters